Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03887884 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)
A Phase 1 study, sponsored by Acorda Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT03887884 is a Phase 1 study that has completed, run by Acorda Therapeutics. The registered enrollment target is 23 participants.
The verdict
NCT03887884, a Phase 1 study, has completed, sponsored by Acorda Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study will be an open-label, randomized, multi-center, 2-way crossover Pharmacokinetic PK evaluation of a single inhaled dose of CVT-301 84 mg and a single oral dose of carbidopa/levodopa CD/LD 25 mg/100 mg (Sinemet®) under fed conditions in Parkinson's Disease (PD) patients who regularly take CD/LD.
Interventions
- DRUG CVT-301
- DRUG Sinemet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2019-03-05 |
| Est. Completion | 2019-06-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03887884
The ClinicalTrials.gov registry entry for NCT03887884 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acorda Therapeutics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CVT-301 is the first listed.
NCT03887884 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03887884 about?
NCT03887884 is a clinical study titled "Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)". This study will be an open-label, randomized, multi-center, 2-way crossover Pharmacokinetic PK evaluation of a single inhaled dose of CVT-301 84 mg and a single oral dose of carbidopa/levodopa CD/LD 25 mg/100 mg (Sinemet®) under fed conditions in Parkinson's Disease (PD) patients who regularly take ...
What is the current status of trial NCT03887884?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2019-03-05. Estimated completion is 2019-06-28.
What interventions are being tested in trial NCT03887884?
The interventions under investigation include: CVT-301 (DRUG), Sinemet (DRUG).
Who is sponsoring clinical trial NCT03887884?
This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.